Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)

Maravai LifeSciences raises 2026 Adjusted EBITDA guidance as Q2 revenue rises 8.5%

Positive Impact 4 of 5 guidance Written later

Maravai LifeSciences reported second quarter 2026 revenue of $51.4 million, up 8.5% from the prior year, and a net loss of $21.6 million, compared with a net loss of $69.8 million in the second quarter of 2025. The company raised its full year 2026 Adjusted EBITDA guidance to $33 million to $35 million, from $30 million to $32 million, and reiterated its full year 2026 revenue guidance of $205 million to $215 million.

Key points

  • Q2 2026 revenue was $51.4 million, up 8.5%; TriLink rose 11.5% and Cygnus rose 2.8%.
  • Net loss narrowed to $21.6 million from $69.8 million a year earlier; net loss attributable to Maravai shareholders was $12.4 million.
  • Net loss per Class A common share was $(0.08), compared with $(0.27) in the second quarter of 2025.
  • Full year 2026 Adjusted EBITDA (non-GAAP) guidance raised to $33.0 million to $35.0 million; revenue guidance of $205.0 million to $215.0 million reiterated.

The filing

CompanyMARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:05 PM ET
Accession number0001823239-26-000056

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.